Effect of renal ischemia on plasma levels of FK 506 in rats.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 2954665)

Published in Transplant Proc on February 01, 1992


M Sakr1, G Zetti, J Gavaler, H Farghali, R Venkataramanan, G Carrieri, T Starzl, D Van Thiel

Author Affiliations

1: Department of Surgery, University of Pittsburgh, School of Medicine, Pennsylvania.

Articles by these authors

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03


Liver transplantation (1). N Engl J Med (1989) 4.53

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet (1986) 3.53


The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Liver transplantation (2). N Engl J Med (1989) 2.93


Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J (1999) 2.61

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther (1985) 2.38

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

The hepatotropic influence of cyclosporine. Surgery (1990) 2.27

Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol (1988) 2.21

Left hepatic trisegmentectomy. Surg Gynecol Obstet (1982) 2.16

Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96

Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89

Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83

Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75

Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm (1995) 1.69

Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67

Cyclosporine A augments the regenerative response after partial hepatectomy in the rat. Transplant Proc (1988) 1.64

Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis (1985) 1.61

Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61

The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58

Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients. Transplant Proc (1985) 1.55

The cellular defect in alpha 1-proteinase inhibitor (alpha 1-PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA. Proc Natl Acad Sci U S A (1985) 1.51

Orthotopic liver transplantation for alcoholic cirrhosis. JAMA (1988) 1.45

Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol (1989) 1.45

Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41

Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc (1988) 1.38

Autopsy findings in a long-surviving liver recipient. N Engl J Med (1973) 1.36

Paradoxes in longevity: sequence analysis of mtDNA haplogroup J in centenarians. Eur J Hum Genet (2001) 1.36

FK 506 as a growth control factor. Transplant Proc (1990) 1.36

Neurologic complications of FK 506. Transplant Proc (1991) 1.34

Assay of FK 506 in plasma. Transplant Proc (1990) 1.32

Sensitivity of activated human lymphocytes to cyclosporine and its metabolites. Hum Immunol (1988) 1.31

The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos (1999) 1.30

Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. Hepatology (1991) 1.30

Canine total orthotopic small bowel transplantation under FK 506. Transplant Proc (1991) 1.29

Excretion of cyclosporine and its metabolites in human bile. Transplant Proc (1986) 1.27

Gene/longevity association studies at four autosomal loci (REN, THO, PARP, SOD2). Eur J Hum Genet (1999) 1.25

Successful sequential liver-kidney transplantation in a patient with performed lymphocytotoxic antibodies. Transplant Proc (1987) 1.25

Role of bile and bile salts on cyclosporine absorption in dogs. Transplant Proc (1987) 1.24

Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc (1991) 1.24

Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23

Comparison of UW with other solutions for liver preservation in dogs. Clin Transplant (1989) 1.20

Liver transplantation in older patients. N Engl J Med (1987) 1.20

Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc (1991) 1.19

Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted? Transplantation (1994) 1.18

Age-related changes of the 3'APOB-VNTR genotype pool in ageing cohorts. Ann Hum Genet (1998) 1.18

Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18

Phylogenetic analysis of serotype A foot-and-mouth disease virus isolated in India between 1977 and 2000. Arch Virol (2002) 1.18

Disease gravity and urgency of need as guidelines for liver allocation. Hepatology (1994) 1.16

Effective removal of copper by plasma exchange in fulminant Wilson's disease. Transfusion (1998) 1.14

Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc (1990) 1.14

Hepatic resection for cystic lesions of the liver. Ann Surg (1993) 1.14

Accuracy of computerized tomography in determining hepatic tumor size in patients receiving liver transplantation or resection. J Clin Oncol (1984) 1.13

Effect of Cyclosporin-A on Hepatic and Renal Allograft Mononuclear Cell Infiltration. Transplant Proc (1983) 1.11

Effect of erythromycin on cyclosporine levels. N Engl J Med (1985) 1.09

Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. Transplant Proc (1990) 1.08

Fructose protects rat hepatocytes from anoxic injury. Effect on intracellular ATP, Ca2+i, Mg2+i, Na+i, and pHi. J Biol Chem (1992) 1.08

Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol (1987) 1.07

Effect of anoxia on intracellular ATP, Na+i, Ca2+i, Mg2+i, and cytotoxicity in rat hepatocytes. J Biol Chem (1992) 1.06

Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology (1992) 1.06

Large hiatal hernias, anemia, and linear gastric erosion: studies of etiology and medical therapy. Am J Gastroenterol (1992) 1.06

Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc (1991) 1.06

FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. Hepatology (1991) 1.05

Antipyrine kinetics in liver disease and liver transplantation. Clin Pharmacol Ther (1986) 1.03

Quality of life before and after orthotopic hepatic transplantation. Arch Intern Med (1991) 1.03

Cyclosporine. Drug Intell Clin Pharm (1985) 1.02

Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci (2010) 1.02

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02

Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986. Transplantation (1989) 1.02

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem (1998) 1.01

Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother (2010) 1.01

Inhibition of liver, kidney, and intestine regeneration by rapamycin. Transplantation (1992) 1.00

The effect of hepatic stimulatory substance, isolated from regenerating hepatic cytosol, and 50,000 and 300,000 subfractions in enhancing survival in experimental acute hepatic failure in rats treated with D-galactosamine. Hepatology (1987) 0.99

FK 506 dosage in human organ transplantation. Transplant Proc (1990) 0.99

Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc (2005) 0.98

The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. Transplantation (1992) 0.98

Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant (1991) 0.96

Interferon-alpha-induced acute renal allograft rejection. Transplantation (1995) 0.95

Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells. Transplant Proc (1988) 0.95

Skin tags: a cutaneous marker for colonic polyps. Ann Intern Med (1983) 0.95

Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. J Pharmacol Exp Ther (1998) 0.95

Genetic diversity in the VP1 gene of foot-and-mouth disease virus serotype Asia 1. Arch Virol (2002) 0.94